SCHEMBL5963243

SCHEMBL5963243

CC(C)(C)c1c(F)cc(F)cc1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 5/20 0.44
CES1 P23141 5/20 0.44
KEAP1 Q14145 2/20 0.40
RIPK1 Q13546 4/20 0.38
NOTUM Q6P988 3/20 0.37
NR1H4 Q96RI1 2/20 0.36
EPHX2 P34913 1/20 0.36
KDM4E B2RXH2 2/20 0.36
ALB P02768 2/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
DHFR P00374 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
LMNA P02545 1/20 0.36
TTR P02766 1/20 0.36
HMGB1 P09429 1/20 0.36
HPGD P15428 1/20 0.36
CXCL12 P48061 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1690169 0.77 TDP1 (0.40) CES2CES1KEAP1NOTUMNR1H4
SCHEMBL12086412 0.76 RIPK1 (0.36) CES2CES1RIPK1ALDH1A1CA1
SCHEMBL5857864 0.74 CES2 (0.48) CES2CES1KEAP1NOTUMKDM4E
SCHEMBL29657075 0.74 CES2 (0.48) CES2CES1KEAP1NOTUMKDM4E
SCHEMBL14703661 0.74 MAPK1 (0.44) CES2CES1NR1H4EPHX2KDM4E
SCHEMBL10222518 0.73 ALB (0.55) CES2CES1NOTUMNR1H4EPHX2
SCHEMBL1421628 0.73 CES2 (0.71) CES2CES1KEAP1KDM4EALB
SCHEMBL28460683 0.72 CES2 (0.47) CES2CES1KEAP1RIPK1TTR
SCHEMBL8466122 0.71 CES2 (0.50) CES2CES1KEAP1KDM4EALB
SCHEMBL2791251 0.71 AKR1C2 (0.58) CES2CES1KEAP1KDM4EALB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119073-B2 Peptides and their use as inhibitors of hepatitis C virus ns3 protease ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2006-10-10 US disclosed
US-20040142876-A1 Peptides and their use as inhibitors of hepatitis c virus ns3 protease ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) 2004-07-22 US disclosed
EP-1392721-A1 PEPTIDES AND THEIR USE AS INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2004-03-03 EP disclosed
WO-2002079234-A1 PEPTIDES AND THEIR USE AS INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142876-A1 Peptides and their use as inhibitors of hepatitis c virus ns3 protease CTRL, VIP, CTSC CES2 702/4885CES1 44/4885KEAP1 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.